Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Causes and evaluation of hyperkalemia in adults

Topic Outline

INTRODUCTION

Hyperkalemia is a common clinical problem. Potassium enters the body via oral intake or intravenous infusion, is largely stored in the cells, and is then excreted in the urine. The major causes of hyperkalemia are increased potassium release from the cells and, most often, reduced urinary potassium excretion (table 1).

This topic will review the causes and evaluation of hyperkalemia. The clinical manifestations, treatment, and prevention of hyperkalemia, as well as a detailed discussion of hypoaldosteronism (an important cause of hyperkalemia), are presented elsewhere. (See "Clinical manifestations of hyperkalemia in adults" and "Treatment and prevention of hyperkalemia in adults" and "Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)".)

BRIEF REVIEW OF POTASSIUM PHYSIOLOGY

An understanding of potassium physiology is helpful when approaching patients with hyperkalemia. Total body potassium stores are approximately 3000 meq or more (50 to 75 meq/kg body weight) [1]. In contrast to sodium, which is the major cation in the extracellular fluid and has a much lower concentration in the cells, potassium is primarily an intracellular cation, with the cells containing approximately 98 percent of body potassium. The intracellular potassium concentration is approximately 140 meq/L compared with 4 to 5 meq/L in the extracellular fluid. The difference in distribution of the two cations is maintained by the Na-K-ATPase pump in the cell membrane, which pumps sodium out of and potassium into the cell in a 3:2 ratio.

The ratio of the potassium concentrations in the cells and the extracellular fluid is the major determinant of the resting membrane potential across the cell membrane, which sets the stage for the generation of the action potential that is essential for normal neural and muscle function. Thus, both hyperkalemia and hypokalemia can cause muscle paralysis and potentially fatal cardiac arrhythmias. (See "Clinical manifestations of hyperkalemia in adults" and "Clinical manifestations and treatment of hypokalemia", section on 'Manifestations of hypokalemia'.)

The causes of hyperkalemia can be best understood after a brief review of normal potassium homeostasis. The plasma potassium concentration is determined by the relationship among potassium intake, the distribution of potassium between the cells and the extracellular fluid, and urinary potassium excretion.

                                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Jan 14, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Boddy K, King PC, Hume R, Weyers E. The relation of total body potassium to height, weight, and age in normal adults. J Clin Pathol 1972; 25:512.
  2. Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458:157.
  3. Giebisch GH, Wang WH. Potassium transport--an update. J Nephrol 2010; 23 Suppl 16:S97.
  4. Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009; 71:381.
  5. Mount DB, Zandi-Nejad K. Disorders of Potassium Balance. In: Brenner and Rector's The Kidney, 9th Ed, WB Saunders & Company, Philadelphia 2011. p.640.
  6. Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.
  7. Bundgaard H, Schmidt TA, Larsen JS, Kjeldsen K. K+ supplementation increases muscle [Na+-K+-ATPase] and improves extrarenal K+ homeostasis in rats. J Appl Physiol (1985) 1997; 82:1136.
  8. Jackson CA. Rapid renal potassium adaptation in rats. Am J Physiol 1992; 263:F1098.
  9. Rabelink TJ, Koomans HA, Hené RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.
  10. Palmer LG, Frindt G. Regulation of apical K channels in rat cortical collecting tubule during changes in dietary K intake. Am J Physiol 1999; 277:F805.
  11. Frindt G, Shah A, Edvinsson J, Palmer LG. Dietary K regulates ROMK channels in connecting tubule and cortical collecting duct of rat kidney. Am J Physiol Renal Physiol 2009; 296:F347.
  12. Garg LC, Narang N. Renal adaptation to potassium in the adrenalectomized rabbit. Role of distal tubular sodium-potassium adenosine triphosphatase. J Clin Invest 1985; 76:1065.
  13. Mujais SK. Renal memory after potassium adaptation: role of Na+-K+-ATPase. Am J Physiol 1988; 254:F845.
  14. Smellie WS. Spurious hyperkalaemia. BMJ 2007; 334:693.
  15. Ismail A, Shingler W, Seneviratne J, Burrows G. In vitro and in vivo haemolysis and potassium measurement. BMJ 2005; 330:949.
  16. Don BR, Sebastian A, Cheitlin M, et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322:1290.
  17. Wiederkehr MR, Moe OW. Factitious hyperkalemia. Am J Kidney Dis 2000; 36:1049.
  18. Bailey IR, Thurlow VR. Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann Clin Biochem 2008; 45:266.
  19. Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis 1988; 12:116.
  20. Chumbley LC. Pseudohyperkalemia in acute myelocytic leukemia. JAMA 1970; 211:1007.
  21. Lee HK, Brough TJ, Curtis MB, et al. Pseudohyperkalemia--is serum or whole blood a better specimen type than plasma? Clin Chim Acta 2008; 396:95.
  22. Chawla NR, Shapiro J, Sham RL. Pneumatic tube "pseudo tumor lysis syndrome" in chronic lymphocytic leukemia. Am J Hematol 2009; 84:613.
  23. Kellerman PS, Thornbery JM. Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient. Am J Kidney Dis 2005; 46:746.
  24. Adrogué HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.
  25. Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 2011; 22:1981.
  26. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.
  27. Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med 1977; 297:796.
  28. Finsterer U, Lühr HG, Wirth AE. Effects of acute hypercapnia and hypocapnia on plasma and red cell potassium, blood lactate and base excess in man during anesthesia. Acta Anaesthesiol Scand 1978; 22:353.
  29. SCRIBNER BH, FREMONT-SMITH K, BURNELL JM. The effect of acute respiratory acidosis on the internal equilibrium of potassium. J Clin Invest 1955; 34:1276.
  30. Magner PO, Robinson L, Halperin RM, et al. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis 1988; 11:220.
  31. COHEN JJ, BRACKETT NC Jr, SCHWARTZ WB. THE NATURE OF THE CARBON DIOXIDE TITRATION CURVE IN THE NORMAL DOG. J Clin Invest 1964; 43:777.
  32. Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med 1993; 94:475.
  33. Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.
  34. Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.
  35. Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.
  36. DeFronzo RA, Sherwin RS, Dillingham M, et al. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings. J Clin Invest 1978; 61:472.
  37. Sharma AM, Thiede HM, Keller F. Somatostatin-induced hyperkalemia in a patient on maintenance hemodialysis. Nephron 1991; 59:445.
  38. Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25:3439.
  39. Sargent AI, Overton CC, Kuwik RJ, et al. Octreotide-induced hyperkalemia. Pharmacotherapy 1994; 14:497.
  40. Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.
  41. Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106:c143.
  42. Sirken G, Raja R, Garces J, et al. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis 2004; 43:e31.
  43. Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.
  44. Sever MS, Erek E, Vanholder R, et al. Serum potassium in the crush syndrome victims of the Marmara disaster. Clin Nephrol 2003; 59:326.
  45. Perkins RM, Aboudara MC, Abbott KC, Holcomb JB. Resuscitative hyperkalemia in noncrush trauma: a prospective, observational study. Clin J Am Soc Nephrol 2007; 2:313.
  46. Schaller MD, Fischer AP, Perret CH. Hyperkalemia. A prognostic factor during acute severe hypothermia. JAMA 1990; 264:1842.
  47. Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302:431.
  48. Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 1990; 33:269.
  49. Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 1986; 57:23F.
  50. Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 2:591.
  51. Daut J, Maier-Rudolph W, von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247:1341.
  52. Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37:793.
  53. Struthers AD, Quigley C, Brown MJ. Rapid changes in plasma potassium during a game of squash. Clin Sci (Lond) 1988; 74:397.
  54. Thomson A, Kelly DT. Exercise stress-induced changes in systemic arterial potassium in angina pectoris. Am J Cardiol 1989; 63:1435.
  55. Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.
  56. Knochel JP, Blachley JD, Johnson JH, Carter NW. Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs. J Clin Invest 1985; 75:740.
  57. Sangkabutra T, Crankshaw DP, Schneider C, et al. Impaired K+ regulation contributes to exercise limitation in end-stage renal failure. Kidney Int 2003; 63:283.
  58. Reza MJ, Kovick RB, Shine KI, Pearce ML. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291:777.
  59. Bandara V, Weinstein SA, White J, Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon 2010; 56:273.
  60. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart 2003; 89:e14.
  61. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.
  62. Birch AA Jr, Mitchell GD, Playford GA, Lang CA. Changes in serum potassium response to succinylcholine following trauma. JAMA 1969; 210:490.
  63. Cooperman LH. Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA 1970; 213:1867.
  64. Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632.
  65. Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 1999; 33:782.
  66. Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant 2002; 17:1150.
  67. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 2005; 365:1873.
  68. Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.383, 898.
  69. Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.
  70. Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.
  71. Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.
  72. Luke RG, Allison ME, Davidson JF, Duguid WP. Hyperkalemia and renal tubular acidosis due to renal amyloidosis. Ann Intern Med 1969; 70:1211.
  73. Stokes JB. Potassium secretion by cortical collecting tubule: relation to sodium absorption, luminal sodium concentration, and transepithelial voltage. Am J Physiol 1981; 241:F395.
  74. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998; 274:F817.
  75. Chakko SC, Frutchey J, Gheorghiade M. Life-threatening hyperkalemia in severe heart failure. Am Heart J 1989; 117:1083.
  76. Popovtzer MM, Katz FH, Pinggera WF, et al. Hyperkalemia in salt-wasting nephropathy. Study of the mechanism. Arch Intern Med 1973; 132:203.
  77. Gonick HC, Kleeman CR, Rubini ME, Maxwell MH. Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971; 261:281.
  78. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 6:1134.
  79. Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int 1993; 43:212.
  80. Bonilla S, Goecke IA, Bozzo S, et al. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest 1991; 88:2137.
  81. Bofill P, Goecke IA, Bonilla S, et al. Tissue-specific modulation of Na, K-ATPase alpha-subunit gene expression in uremic rats. Kidney Int 1994; 45:672.
  82. Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007; 22:3471.
  83. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438.
  84. Wrenger E, Müller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147.
  85. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.
  86. Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant 2004; 19:2163.
  87. DeFronzo RA, Cooke CR, Goldberg M, et al. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med 1977; 86:268.
  88. DeFronzo RA, Goldberg M, Cooke CR, et al. Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney Int 1977; 11:357.
  89. DeFronzo RA, Taufield PA, Black H, et al. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med 1979; 90:310.
  90. Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107:548.
  91. West ML, Marsden PA, Richardson RM, et al. New clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab 1986; 12:234.
  92. Ethier JH, Kamel KS, Magner PO, et al. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990; 15:309.
  93. Choi MJ, Ziyadeh FN. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol 2008; 19:424.
  94. Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens 2011; 20:547.